3308-94-9

Basic information

• Product Name: 2-(3-Chloropropyl)-2-(4-fluorophenyl)-1,3-dioxolane
• Synonyms: 2-(3-CHLOROPROPYL)-2-(4-FLUOROPHENYL)-1,3-DIOXALANE;2-(3-CHLOROPROPYL)-2-(4-FLUOROPHENYL)-1,3-DIOXOLANE;TIMTEC-BB SBB005849;2-(3-chloropropyl)-2-(p-fluorophenyl)-1,3-dioxolane;OMEGA-CHLORO-4-FLUOROBUTYROPHENONE ETHY&;5-CHLORO-1-(4-FLUOROPHENYL)-1-BUTANONE ETHYLENE KETAL;2-(3-Chloropropyl)-2-(4-fluorophenyl)-1,3-dioxalane 97%;2-(3-Chloropropyl)-2-(4-fluorophenyl)-1,3-dioxalane97%
• CAS NO: 3308-94-9
• Molecular Formula: C₁₂H₁₄ClFO₂
• Molecular Weight: 244.69
• EINECS: 221-993-9
• Mol File: 3308-94-9.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 162-166 °C (15 mmHg)
• Flash Point: 147.361 °C
• Appearance: clear colourless to faint yellow oily liquid
• Density: 1.219
• Vapor Pressure: 0.00061mmHg at 25°C
• Refractive Index: 1.505-1.5075
• Storage Temp.: Sealed in dry,Room Temperature
• Water Solubility: insoluble
• CAS DataBase Reference: 2-(3-Chloropropyl)-2-(4-fluorophenyl)-1,3-dioxolane(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-Chloropropyl)-2-(4-fluorophenyl)-1,3-dioxolane(3308-94-9)
• EPA Substance Registry System: 2-(3-Chloropropyl)-2-(4-fluorophenyl)-1,3-dioxolane(3308-94-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 37/39-26
• HazardClass: IRRITANT
• Hazardous Substances Data: 3308-94-9(Hazardous Substances Data)

Usage

Chemical Properties

clear colourless to faint yellow oily liquid

InChI:InChI=1/C12H14ClFO2/c13-7-1-6-12(8-15-9-16-12)10-2-4-11(14)5-3-10/h2-5H,1,6-9H2

Upstream product

• 107-21-1 ethylene glycol 
• 3874-54-2 4-(4-fluorophenyl)-4-oxo-n-butyl chloride 
• 462-06-6 fluorobenzene 

Downstream Products

• 55846-41-8 1-(3-[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]-propyl)piperazine 
• 82236-09-7 4-amino-1-<3-(4-fluorobenzoyl)propyl>pyridinium chloride ethylene acetal 
• 65053-27-2 4-(2-aminoanilino)-1-<3-(4-fluorobenzoyl)propyl>pyridinium chloride ethylene acetal 
• 801-12-7 1-(4-fluoro-phenyl)-4-(4-pyrimidin-2-yl-piperazin-1-yl)-butan-1-one 
• 3308-95-0 2-(4-fluorophenyl)-2-(3-phthalimidopropyl)-1,3-dioxolane 
• 56660-98-1 1-<4-(4-fluorophenyl)-4,4-(ethylenedioxy)butyl>-4-piperidinone 
• 79242-38-9 1'-<3-(4-fluorobenzoyl)propyl>-2,3-dihydro-2-phenylspiro 
• 133982-66-8 1-(4-fluorophenyl)-4-[5-(fluoro-2-pyrimidinyl)-1-piperazinyl]butanone 
• 99931-65-4 4-[4-(5-Bromo-pyrimidin-2-yl)-piperazin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one 
• 81960-01-2 <<(ethylenedioxy-4,4 p. fluorophenyl-4 butyl-1)-1 piperidinyl-4> methyl-1 dimethyl-2,6 dihydro-1,4 pyridylidene-4 yl>-2 indanedione-1,3 
• 99931-64-3 4-[4-(5-Chloro-pyrimidin-2-yl)-piperazin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one 
• 144317-69-1 4-[4-(5-Fluoro-4-methylsulfanyl-pyrimidin-2-yl)-piperazin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one 
• 89434-61-7 4-<6,7-Dihydro-spirothiophen-4(5H),3'-pyrrolidin>-1'-yl>-1-(4-fluorphenyl)-1-butanon 
• 145021-98-3 2-(4-Fluoro-phenyl)-1-(1-{3-[2-(4-fluoro-phenyl)-[1,3]dioxolan-2-yl]-propyl}-piperidin-4-yl)-ethanone 

Relevant articles and documents

The synthesis of ω-(2-aryl-1,3-dioxolan-2-yl)alkyl purine derivatives and their activity towards HIV reverse transcriptase

Novel derivatives of 6-substituted purines were synthesized by alkylation of 6-substituted purines with various 2-(chloroalkyl)-2-aryl-1,3-dioxolanes and related compounds. Their inhibitory properties toward HIV reverse transcriptase were studied. The structure-activity relationship within the synthesized compounds was found.

PROTEASE-BINDING COMPOUNDS AND METHODS OF USE

Non-peptide, protease-binding compounds are described as useful in the detection, labelling, and inhibition of retroviral proteases. Aryl piperidinyl derivatives and other compounds related in structure have been found to be HIV-1 and HIV-2 protease-binding compounds.

Synthesis and Biological Characterization of α-(4-Fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and Analogues as Potential Atypical Antipsychotic Agents

A series of 1-(pyrimidin-2-yl)piperazine derivatives were prepared and evaluated in receptor binding assays and in in vivo behavioral paradigms as potential atypical antipsychotic agents.Compound 16 (BMS 181100 (formerly BMY 14802)) emerged as the lead compound from within the series on the basis of its good activity and duration of action in the inhibition of both conditioned avoidance responding and apomorphine-induced stereotopy in the rat.Compound 16 not only failed to induce catalepsy in the rat but was quite effective in reversing the cataleptic effect of neurolepti c agents, thus indicating a low propensity for causing extrapyramidal side effects.In comparison to reference antipsychotic agents, 16 appeared to be less sedating and was relatively weaker in causing muscle incoordination.The compound was essentially inactive in binding to dopamine D2 receptors and its chronic administration to rats did not result in dopamine receptor supersensitivity.It exhibited modest to weak affinity for 5-HT1A and α1 receptors but was found to be a fairly potent ligand for ? binding sites (IC50 vs (+)--3-PPP = 112 nM).Although the resolved enantiomers of racemic 16 did not show dramatic differences from racemate or from each other in most tests, the R(+) enantiomer was up to 11-fold more potent than its antipode in binding to ? sites.Several studies have indicated that 16 may be a limbic-selective agent which may modulate dopaminergic activity by an indirect mechanism.The compound has been selected for clinical evaluation in the treatment of psychosis.